Kanna for Health & Longevity - Quick Reference Sheet

Kanna for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Kanna is a South African succulent plant used as an oral supplement for stress resilience, mental flexibility, and sleep. Standardized oral extract (Zembrin, 25 mg daily) shows moderate evidence for calming the brain's threat response, improving mental flexibility and agility, and helping fall asleep, while anxiety and mood evidence is weak and conflicting. Oral use is well tolerated, avoids antidepressants and unverified powders, and relies on small manufacturer-funded trials. (Full Review)

Protocol

Standardized extract protocol
25 mg/day oral Zembrin
8 mg/day and 50 mg/day oral regimens also studied in human clinical trials
Single versus split dosing
Once daily (oral extract)
Zembrin (8–25 mg) administered orally once daily; fermented herb (50–200 mg/day) once daily, split 2–3 times daily, or chewed sublingually
Optimal time of day
Morning or 1–2 h pre-stressor
Morning for daily cognitive flexibility, or 1–2 hours before acute situational stressors or gratitude practices
Time to effect
Subcortical Threat Circuitry Attenuation
1–2 hours
Single 25 mg oral Zembrin dose dampens amygdala threat reactivity and amygdala-hypothalamus coupling (lasting 4–6 hours)
Executive Function and Complex Reactive Performance
8–21 days
8 days for reactive agility and visual-motor reaction; 3 weeks for executive function and cognitive flexibility at 25 mg/day
Sleep Onset Latency Reduction
2–3 weeks
Daily 25 mg oral Zembrin improves sleep initiation on the HAM-D sleep-onset subscale by week 3

Benefits

Contraindications
  • Pregnant or lactating individuals
  • Individuals with active psychiatric disorders, suicidal risk, or baseline HAM-D score ≥ 8
  • Individuals with hepatic impairment (acute hepatitis, chronic active hepatitis, cirrhosis) or renal failure
  • Individuals with unstable cardiovascular disease (recent myocardial infarction or ischemia, unstable angina, uncontrolled hypertension), epilepsy, or body mass index (BMI) ≥ 30 kg/m2
Key Interactions
  • Prescription antidepressants: SSRIs (fluoxetine, escitalopram), SNRIs (venlafaxine), and MAOIs (phenelzine) (Avoid, theoretical; 14-day washout)
  • Prescription PDE4 inhibitors and sedatives: PDE4 inhibitors (roflumilast, apremilast) and benzodiazepine or Z-drug sedatives (lorazepam, diazepam, zolpidem) (Caution, theoretical)
  • Over-the-counter antitussives and antihistamines: OTC cough suppressants (dextromethorphan) and sedating antihistamines (diphenhydramine, doxylamine) (Caution, theoretical)
  • Serotonergic dietary supplements: 5-HTP, L-Tryptophan, St. John's wort, SAMe, and Rhodiola rosea (Avoid, theoretical; 72-hour washout)
  • Alcohol, cannabis, and monoamine releasers: Ethanol, Cannabis sativa, and MDMA (Avoid, theoretical)

Risk & Side Effects

  • High:
  • Medium: Subjective fatigue and mild sedation; increased appetite, thirst, and self-reported weight gain
  • Low: Transient gastrointestinal discomfort and headache; commercial supplement adulteration and sympathomimetic contamination
  • Speculative: Oxalate mucosal irritation and nephrolithiasis risk; adrenal androgen and cortisol suppression; supratherapeutic ataxia and cortical glutathione depletion

Monitoring

Marker Target Why
HAM-D Score < 8 points (conventional reference range: 0–7 points) Safety check and expected change: screens out clinical depression (≥ 8 points excludes self-directed use) and tracks sleep-onset subscale improvement.
Seated Heart Rate (Resting and Post-Stressor) No established target; blunting of pre-stressor heart rate rise from individual baseline Expected change and safety check: 25 mg Zembrin blunts anticipatory heart rate spikes; resting tachycardia (> 100 beats per minute) is a discontinuation threshold (paired with seated blood pressure).
Computerized Executive Function & Cognitive Flexibility No established target; improvement from individual baseline score Expected change: 25 mg/day Zembrin improved executive function and cognitive set flexibility scores over 3 weeks on the CNS Vital Signs battery.
Morning Serum Cortisol & Total Testosterone Cortisol: 5–25 mcg/dL; Testosterone: 300–1,000 ng/dL in males, 15–70 ng/dL in females (standard reference range) Safety check: high-mesembrine extract inhibits adrenal CYP17A1, 3β-HSD, and 17β-HSD in vitro; values falling below range warrant discontinuation (paired with free testosterone and LH at 3 months).

Cadence: Baseline (HAM-D score, seated heart rate and blood pressure, computerized executive function, morning fasting cortisol and total testosterone, plus baseline-only complete blood counts, metabolic panels, and liver-kidney tests to screen out hepatic or renal impairment); week 1 (seated heart rate and blood pressure, 60–120 min post-dose); weeks 3–4 (executive cognition 1–2 h post-dose and sleep-onset latency); every 3–6 months (morning fasting cortisol, total and free testosterone, and LH).

Qualitative Assessment

  • Anticipatory calm: Lower stress reactivity in 1–2 hours.
  • Sleep onset: Faster sleep initiation in 2–3 weeks.
  • Task-switching: Smoother set-shifting in 1–3 weeks.
  • Tolerability: No tiredness or nausea.